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Abstract
Background: Ayahuasca is a botanical hallucinogenic preparation traditionally used by indigenous populations of Northwestern Amazonian countries for 
ritual and therapeutic purposes. It is rich in β-carboline alkaloids and N,N-dimethyltryptamine (DMT). Preclinical, observational, and experimental studies 
suggest that ayahuasca and its alkaloids have anxiolytic and antidepressive effects. We recently reported in an open-label trial that ayahuasca administration 
was associated with significant decreases in depression symptoms for 2-3 weeks after the experimental session in 17 patients with treatment-resistant major 
depressive disorder. Objectives: To investigate if the experiment had any long-lasting effects on patients Methods: Eight patients were interviewed 4 to 7 years 
after ayahuasca intake. Results: Our results suggest that ayahuasca was well tolerated and that symptom reductions were limited to a few weeks. Importantly, 
most patients believed that the experience was among the most important of their lives, even 4-7 years later. Discussion: To the best of our knowledge, this is 
the first long-term follow-up of a clinical sample that participated in an ayahuasca trial. Further studies with different and repeated dosing should be designed 
to further explore the antidepressive and anxiolytic effects of ayahuasca.
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Introduction
Ayahuasca is a botanical hallucinogenic preparation traditionally 
used by indigenous populations of Northwestern Amazonian 
countries for ritual and therapeutic purposes1, and also as a sacrament 
and therapeutic tool by Brazilian syncretic religions such as the Santo 
Daime, Barquinha and União do Vegetal2,3. It is usually prepared by 
the prolonged concoction of the bark of the vine Banisteriopsis caapi 
together with the leaves of the shrub Psychotria viridis. The vine is rich 
in β-carboline alkaloids such as harmine, tetrahydroharmine (THH), 
and harmaline, and P. viridis contains N,N-dimethyltryptamine 
(DMT). The β-carbolines act as reversible inhibitors of monoamine 
oxidase (MAO)-A, and DMT act as a 5-HT1A/2A/2C agonist4. DMT by 
itself is not orally active due to degradation by peripheral MAO-A, 
but MAO-A inhibition by the β-carbolines renders DMT active by 
allowing it to reach the brain4-6. The neural basis of the effects of 
ayahuasca seem to involve modulation of frontal and midline brain 
structures, such as the default mode network (DMN)5-9. 
Preclinical, observational, and experimental studies suggest 
that ayahuasca and its alkaloids have anxiolytic, antidepressive, and 
antiaddictive effects2,3,10-14, and studies with healthy volunteers2-8 
and psychiatric patients10,11 show that it is well tolerated. Previous 
observational studies assessing the mental health of members of 
Brazilian ayahuasca churches described the potential effects of regular 
ayahuasca use on anxiety, depression and dependence symptoms2,14. 
Moreover, the first double-blind, controlled study showing that 
a single ayahuasca dose induced significant reductions on panic-
like and depressive symptoms was conducted among Santo Daime 
members3.
We recently reported that administration of a single oral dose 
of ayahuasca (dose: 2.2 mL/kg; alkaloid content in the sample: 0.8 
mg/mL DMT, 0.21 mg/mL harmine, no harmaline was detected, 
and THH was not analyzed due to a lack of analytical requirements) 
in an open-label trial to 17 patients with treatment-resistant major 
depressive disorder (MDD) was associated with significant decreases 
in depression symptoms assessed with the Hamilton Rating Scale 
for Depression (HAM-D) and the Montgomery-Åsberg Depression 
Rating Scale (MADRS) from 80 minutes to day 2110,11. Average 
baseline score in the HAM-D scale was 19.24 (SD = 5.52), and at 
day 21 the average score was 7.56 (SD = 4.7). We recently replicated 
these results in a parallel arm, double-blind, randomised, placebo-
controlled trial with 35 patients with treatment-resistant MDD15. 
Compared to placebo, HAM-D scores at day 7 were significantly 
lower in patients treated with ayahuasca (Cohen’s d = 0.98), and 
MADRS scores were significantly reduced in the ayahuasca group 
at days 1, 2 and 7.
After the publication of the open-label study10,11; we were 
interested in interviewing the volunteers after a long-time period 
to ask if the experiment had any long-lasting effects on them. To 
the best of our knowledge, this is the first long-term follow-up of a 
clinical sample that participated in an ayahuasca trial. 
Methods
An experienced psychiatrist that was closely involved with the 
volunteers during the study (RFS) tried to contact the volunteers by 
telephone. At least three attempts, in three different times of the day, 
were made to try to contact the volunteers. The contacted volunteers 
were then asked the following questions by a telephone interview: 
#1.  Do you classify your experience with ayahuasca as negative, 
neutral, or positive? 
#2.  Did the experience bring any significant changes (positive or 
negative) to your life in general? 
#3.  Did the experience bring any significant changes (positive or 
negative) to your daily life? 
#4.  Did the experience bring any significant changes (positive or 
negative) to your relationship with other people (friends, family, 
or in your work)? 
#5.  Did the experience bring any significant changes (positive or 
negative) to your spirituality/religiosity or in your way to see 
the world and nature? 
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#6.  Did the experience bring any significant changes (positive or 
negative) in the way you perceive music or art in general? 
#7.  After the experiment, did you have desire to drink ayahuasca 
again? 
#8.  After the experience, have you used ayahuasca? If yes, how 
many times? Briefly describe the experience. 
#9.  How did your symptoms evolved since the experience? They 
improved, got worse, or remained stable? 
#10. Have you changed your medications after the experience? 
Did you stop taking your medications, returned to the same 
medications, or increased the dose or number of medications? 
#11.  Did you observe any kind of changes in your behavior or 
symptoms during or after the experience that you believe is 
important to mention? 
#12.  Would you classify the experience among the 10 most important 
experiences of your life? In which position, from 1 to 10? 
#13.  If you passed for a difficult and challenging experience during 
the study, do you think it was positive anyway? 
#14.  Did you observe something negative or positive during the 
experience that you think is important to mention? 
Questions #1 to #13 could be answered as positive (+), negative 
(-), or neutral/stable (=). Question #14 could be answered more freely. 
Results
The results of the interview are described in Table 1.
Of the 17 patients that participated in the study, we could contact 
only eight (seven women; mean age 39.87 years; range 28-54). The 
other nine patients could not be contacted after several attempts. All 
the non-participant subjects were not able to be located, thus, there 
were no subjects that refused to participate in the study.
The contacted patients had a mean baseline HAM-D score of 
20.37 (range 17-24) and a mean baseline MADRS score of 27.12 
(range 21-32). Means HAM-D and MADRS scores on D21 were 
6.75 (range 2-15) and 8.75 (range 1-19), respectively. Patients have 
participated in the experiment from October 2010 (patient #1) 
to January 2013 (patient #8), and the follow-up interviews were 
conducted from January to May 2017. Therefore, patients were 
interviewed after a mean of 56.37 months (range 49-76), or 4.7 years.
As can be observed in Table 1, although volunteers had difficult 
experiences, most of them reported that participation on the study 
was positive and had a positive impact on their general and daily lives, 
and that they would like to experiment ayahuasca again (although 
none did). Furthermore, six patients reported that the experience 
was among the 10 most important experiences of their lives, with 
four patients reporting that the experience was among the five most 
important experiences of their lives.
However, four patients reported neutral effects or that their 
symptoms remained stable, nine reported that their medications were 
unchanged (one reported that the medication was changed, and none 
have stopped the medication), and almost all patients that reported 
positive effects also noted that they were short-lived. Furthermore, 
only three patients reported improvements in their relationships with 
friends, family, or at work, and only one described a positive effect 
of the experiment on music and art perception and on spirituality/
religiosity or in the way one sees the world and nature. Negative 
effects included mostly nausea and vomiting. 
Discussion
Previous observational studies in members of the Brazilian ayahuasca 
churches reported the potential effects of ayahuasca on anxiety and 
mood regulation3,14. Moreover, a controlled study in members of 
these groups also reported anxiolytic and antidepressive effects3, 
which were corroborated in recent open-label and controlled studies 
with depressed patients10,11,15. In the present work, the first long-term 
follow-up of those depressed volunteers11, we found that ayahuasca 
was well tolerated and associated with antidepressive effects. 
The main limitations of this follow-up are the long time that 
passed since the experimental session was conducted and that not all 
volunteers were contacted. The first limitation could have increased 
the chances of recollection bias in the sample, and the second makes 
it impossible to know if the other volunteers had the same kind of 
responses, thus limiting the extrapolation of the results for the whole 
sample. Nevertheless, to the best of our knowledge, this is the first 
study long-term follow-up of depressed patients that have ingested 
ayahuasca. 
Even considering the above-cited limitations, our results suggest 
that ayahuasca was well tolerated by these patients and that the 
reductions in depressive symptoms attributed to ayahuasca intake 
were limited to a few weeks. Moreover, most patients that participated 
in the interview believed that the experience was among the most 
important of their lives, even 4-7 years later. This last observation 
could be related to the fact the patients had been suffering with their 
depressive symptoms for a long time, and a significant (although 
limited in time) improvement in their symptoms could have a great 
significance for them. 
The results and limitations of this qualitative study suggest that 
future studies involving administration of ayahuasca should try to 
perform follow-ups after shorter periods of time to try to observe 
any effects that could appear a few months of the experiments and 
to try to avoid losing contact with the volunteers, so that a clearer 
image of the results can be achieved. Furthermore, the present results 
and the data from our open-label and controlled studies suggest that 
Table 1. Depressive symptoms assessed with the Hamilton Depression Rating Scale (HAM-D) and the Montgomery-Åsberg Depression Rating Scale 
(MADRS) and results from the follow-up questions
Age at the 
time of the 
experiment
Time 
since the 
experiment
(months)
HAM-D / 
MADRS
(baseline)
HAM-D / 
MADRS
(D1)
HAM-D / 
MADRS
(D7)
HAM-D / 
MADRS
(D14)
HAM-D / 
MADRS
(D21)
#1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 #13
Patient 1 31 76 20 / 27 14 / 12 3 / 6 3 / 3 2 /1 = = = = = = - - = = × - =
Patient 2 36 67 20 / 32 9 / 17 11 / 7 4 / 2 2 / 3 + + + + + + + - + ≠ + + (6) +
Patient 3 38 52 20 / 32 3 / 1 7 / 11 2 / 2 4 / 2 = = + + = = - - + = + + (4) +
Patient 4 46 55 17 / 21 10 / 12 8 / 15 10 / 151 13 / 15 =/- + = = = = - - = = +/= - +
Patient 5 39 51 20 / 28 17 / 20 18 / 22 15 / 18 15 / 19 + + + = = = + - + = = + (8) +
Patient 6 54 51 19 / 23 6 / 3 10 / 9 16 / 14 5 / 8 + + + = = = - - = = = + (5) +
Patient 7 28 50 23 / 25 5 / 7 5 / 5 6 / 6 5 / 5 = + = + = = - - = = = + (3) +
Patient 8 47 49 24 / 29 13 / 17 20 / 23 16 / 19 10 / 17 + = = = = = + - + = = + (4) +
Ayahuasca intake for these eight patients occurred between October 2010 and January 2013. Interviews were conducted between January and May 2017.
+: positive, -: negative, =: neutral/stable; ≠: changed medication; ×: do not remember. 
The numbers in parenthesis on question #12 are the position from 1 to 10 reported by those volunteers that had a positive answer to that question.
1 Missing data: mean of D7 and D21.
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ayahuasca holds some promise as a viable treatment for refractory 
depression. Nevertheless, future studies designed to further explore 
the antidepressive and anxiolytic effects of ayahuasca should be 
performed with more volunteers, different doses and also with 
repeated dosing for longer periods of time.
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